Related Experiment Video
Updated: May 12, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Role of antiarrhythmic therapy for atrial fibrillation]
Insights
Atrial fibrillation (AF) management focuses on restoring sinus rhythm, but current drugs have limitations. Individualized treatment is crucial, especially for older adults, with amiodarone showing potential for rhythm maintenance.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia.
- AF significantly elevates risks of thromboembolism and mortality.
- Prevalence increases with age, affecting 5.9% of individuals 65+.
Purpose of the Study:
- To review current pharmacological strategies for maintaining sinus rhythm in AF patients.
- To evaluate the efficacy and limitations of existing antiarrhythmic drugs.
- To highlight the need for individualized treatment, particularly in the elderly population.
Main Methods:
- Review of current European guidelines for AF management.
- Analysis of pharmacological therapies for rhythm control in AF.
- Discussion of drug-specific efficacy, side effects, and pro-arrhythmic potential.
Main Results:
- Pharmacological therapy can alleviate AF-related symptoms.
- Amiodarone demonstrates significant potential for sinus rhythm maintenance in older patients.
- Existing antiarrhythmic drugs (flecainide, propafenone, sotalol, dronedarone, vernakalant) have limitations.
Conclusions:
- No universal consensus exists for AF management, necessitating individualized approaches.
- Elderly patients, comprising the majority of AF cases, require tailored therapeutic evaluations.
- Balancing efficacy and safety is paramount in selecting antiarrhythmic therapy for AF.
Abstract:
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and is associated with a significantly increased risk of thromboembolic events and mortality. From the age of 50 years, prevalence of AF doubles every 10 years, being more common in males and reaching 5.9% in patients 65 years and older. The treatment of AF has as first objective the restoration and maintenance of sinus rhythm. The drugs used to date present several limitations in terms of side and pro-arrhythmic effects, associated with a limited antiarrhythmic effect. Recent European guidelines for the management of AF have pointed out that the pharmacological antiarrhythmic therapy to maintain sinus rhythm is helpful for symptoms related to the arrhythmia. Amiodarone is the drug with the greatest potential for maintenance of sinus rhythm in the older population as well. Other drugs currently in use are flecainide, propafenone, sotalol, and more recently introduced dronedarone and vernakalant. To date, there is no consensus among scientific societies on the management of AF: for elderly patients, who account for the majority of patients with AF, a strictly individualized evaluation is mandatory.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

